WuXi, Regeneron In Buying Range Despite Market's Woes

 By Scott Stoddard, Investor's Business DailyPosted 04:40 PM ET Medical stocks WuXi PharmaTech (WX) and Regeneron Pharmaceuticals (REGN) are in buying range after holding up relatively well amid the market's post-election sell-off.China-based WuXi — an outsourcing company offering pharmaceutical, biotechnology and medical device research — is just above a 15.10 buy point in a long base.The stock has an alternative buy point at 15.70, which WuXi topped Thursday but in light trade. WuXi broke out above the 15.10 buy point Monday following a better-than-expected 16% rise in Q3 profit. Volume was just 28% above normal, but it picked up the next day, rising 126% as the stock hit a new high.The stock is thinly traded and WuXi's profit and sales growth, though slow and steady, is weak compared with typical growth companies.In this regard, WuXi is like many other stocks in the Spotlight screen: The fundamentals are not ideal, but the stock has some relative strength, which aggressive investors might consider for purchase.Another medical-sector stock with a better profile is Regeneron.The stock is just above its 142.06 cup-with-handle buy point. The stock has been trading below the 50-day moving average for nearly three weeks, despite that it soundly beat expectations Oct. 24 with its third-quarter profit.Regeneron posted a profit of 37 cents a share in Q1. Second-quarter profit picked up to 90 cents, following a profit of $1.89 in Q3.After many years of losses, the company is on track for a profit this year.Sales growth has picked up in the past two quarters, from a gain of 107% in Q1 to subsequent rises of 182% and 292%.